Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. (Q38566383)

4 September 2017

Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. (English)

1 reference

4 September 2017

Arpan Patel

1

1 reference

4 September 2017

Suna Yapali

series ordinal

2

1 reference

4 September 2017

Anna S F Lok

series ordinal

3

1 reference

4 September 2017

language of work or name

1 reference

14 August 2015

1 reference

4 September 2017

Hepatology international

1 reference

4 September 2017

10

1 reference

4 September 2017

139-146

1 reference

4 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-015-9659-4

4 September 2017

0 references

cites work

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

JSH Guidelines for the Management of Hepatitis B Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-015-9659-4

Redevelopment of hepatitis B surface antigen after renal transplantation

21 January 2018

1 reference

12 December 2020

Screening for hepatitis B in chemotherapy patients: survey of current oncology practices

1 reference

12 December 2020

Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome

1 reference

12 December 2020

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

1 reference

12 December 2020

10.1007/S12072-015-9659-4

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference